Summary of NeuroPace Conference Call Company Overview - **Company**: NeuroPace - **Industry**: MedTech, specifically focused on neuromodulation for epilepsy treatment Key Points and Arguments Commercial Momentum and Growth Drivers - NeuroPace has experienced significant growth in its core RNS (Responsive Neurostimulation) business, particularly in focal drug-resistant epilepsy, driven by: 1. **Increased Adoption and Utilization**: Focus on comprehensive epilepsy centers has led to more prescriptions and higher utilization rates [5][6] 2. **Referral Management Improvements**: Investments in identifying and managing patient referrals have streamlined the diagnostic process [6] 3. **Commercial Execution**: Strengthened sales leadership and ongoing investments in the commercial team have contributed to growth [6] Market Position and Technology Differentiation - NeuroPace's RNS technology is unique as it is the only closed-loop neuromodulation device, allowing for real-time monitoring and tailored therapy for patients [7][10] - The company is focused on expanding clinical indications and developing a robust product pipeline to further differentiate its technology [10] 2026 Financial Outlook - Guidance for 2026 is projected at $98 million to $100 million, with potential upside driven by: - Increased productivity and focus of the sales force [12] - Introduction of new products like SeizureID, aimed at improving physician efficiency [13] - Anticipated approval of the idiopathic indication from the NAUTILUS trial [14] Patient Flow and Market Penetration - Approximately 75,000 patients cycle through comprehensive epilepsy centers annually, indicating a modest penetration rate for RNS implants [16] - No structural barriers are identified that limit penetration; the focus is on educating clinicians and patients to facilitate adoption [17] Project CARE Initiative - The initiative has successfully broadened access to RNS beyond Level 4 centers, improving education and referral processes [20][21] Reimbursement Landscape - Positive momentum in reimbursement, with stable DRG codes and efforts to enhance physician reimbursement for monitoring patients [24][26] - Approximately 20% of the payer mix consists of traditional Medicare, with 30% from Medicare Advantage and 50% from private payers [27] NAUTILUS Trial and FDA Submission - The PMA submission for the idiopathic generalized patient population has been accepted by the FDA, indicating a productive dialogue and high-quality submission [30] - The trial demonstrated a 77% median seizure reduction rate in a highly refractory population, with a low complication rate [36] Market Opportunity - In the U.S., there are about 3.6 million people with epilepsy, with 1.2 million classified as drug-resistant. The idiopathic generalized group represents a significant subsegment of this population [41][42] - The absence of approved devices for idiopathic generalized epilepsy positions NeuroPace to capture a substantial market share upon FDA approval [43] Commercial Strategy and Drug Interaction - NeuroPace aims to work alongside pharmaceutical advancements, recognizing that a significant portion of epilepsy patients remain drug-resistant despite numerous drug approvals [51][52] - The RNS System is designed to complement drug therapies, providing a unique approach to managing epilepsy [52] Additional Important Insights - The company is proactive in preparing for market access and reimbursement processes ahead of potential FDA approval, indicating a strategic approach to commercial readiness [46][48] - The focus on patient safety and efficacy in clinical trials is emphasized as a critical factor for clinician adoption and patient trust [35][36]

Core Insights - NeuroPace reported a total revenue of $26.6 million for Q4 2025, reflecting a 24% year-over-year increase, primarily driven by RNS System sales which reached $22.4 million, up 26% from the previous year [3][7] - The company anticipates a long-term growth trajectory of at least 20% in its core RNS business within the current adult focal epilepsy indication [2] - For the full year 2025, total revenue was $100 million, a 25% increase year-over-year, with RNS System sales also up 25% [12] Financial Performance - Gross margin for Q4 was 77.4%, an improvement from 75.4% in the prior year, driven by higher-margin RNS revenue and improved manufacturing efficiency [8] - Adjusted EBITDA was positive at $0.9 million for the second consecutive quarter, with a net loss of $2.7 million, improved from $5.3 million a year earlier [9][13] - Operating expenses for Q4 were $22.3 million, up from $19.8 million a year ago, but growth remained below revenue growth, indicating operational leverage [9] Regulatory and Product Development - The FDA accepted a PMA supplement to expand RNS into idiopathic generalized epilepsy, with a 180-day review period initiated [5][20] - The AI-enabled SeizureID platform is expected to be approved in H1 2026, aimed at enhancing clinician efficiency [5][22] - NeuroPace is also advancing remote care initiatives, allowing physicians to adjust therapy settings during telehealth visits [23] Future Guidance - For 2026, the company reiterated revenue guidance of $98–100 million on a continuing-operations basis, implying underlying RNS growth of 20–22% [6][15] - The company expects adjusted operating expenses of $90–92 million and an adjusted EBITDA loss of $9–10 million for 2026 [19] - For Q1 2026, revenue is expected to be between $21 million and $22 million, with growth rates typically moderating in the first half of the year [16]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $26.6 million, representing a 24% year-over-year growth compared to $21.5 million in the prior year quarter [4][18] - RNS System revenue was $22.4 million, up 26% year-over-year, contributing significantly to overall revenue growth [4][18] - Gross margin improved to 77.4%, up from 75.4% in the fourth quarter of 2024, driven by higher margin RNS revenue and manufacturing efficiencies [19] - Adjusted EBITDA was positive at $900,000 for the fourth quarter, marking a $1.9 million improvement year-over-year [22] Business Line Data and Key Metrics Changes - The core RNS business showed strong performance with a growth rate of 29% in the second half of 2025 [5] - Service revenue from data collaborations totaled approximately $890,000 in the fourth quarter [18] - Revenue from DIXI Medical was approximately $3 million, a decline of 4% compared to the fourth quarter of 2024, as the company worked to sell existing inventory before the end of the commercial partnership [18] Market Data and Key Metrics Changes - The majority of growth came from Level 4 centers, indicating increased adoption and utilization of the RNS System [6] - The company reached new highs in prescribers, accounts, and patient pipeline, reflecting broad-based momentum across the business [5] Company Strategy and Development Direction - The company is focused on deepening adoption within the adult focal epilepsy indication while preparing for future indication expansion [5] - Investments are being made in the commercial organization, including sales representative additions and nurse navigator resources to enhance patient navigation through the treatment process [9] - The company aims to expand its RNS therapy access through community pathways and improve referral management [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a long-term growth trajectory of at least 20% in the core RNS business [7] - The company reiterated its full-year 2026 revenue guidance of $98 million to $100 million, assuming core RNS growth of 20%-22% [8][26] - Management highlighted the potential for a transformational year in 2026, driven by ongoing market momentum and new product developments [17][34] Other Important Information - The company submitted a PMA supplement to the FDA for an expanded indication in idiopathic generalized epilepsy (IGE), supported by significant clinical data [10] - The SeizureID tool, designed to enhance physician workflow and improve patient outcomes, is expected to receive approval in the first half of 2026 [12] Q&A Session Summary Question: How quickly can the company translate from IGE approval to revenue collection? - Management indicated that extending coverage in the private payer community is essential and that preparations are already underway to target key payers [38] Question: What is the impact of pricing on RNS growth in the fourth quarter? - Management noted that mid-single digit pricing increases have been consistent, contributing positively to gross margins without any significant changes in Q4 [50] Question: What is the current state of capacity dynamics across implanting centers? - Management stated that there is sufficient capacity in the channel for prescribers and that nurse navigators are being employed to facilitate patient flow through the referral process [60][61] Question: What is the logistics behind the SeizureID opportunity? - SeizureID will be part of the RNS System offering, aimed at improving efficiency for clinicians without additional costs for access [66]

Financial Data and Key Metrics Changes - NeuroPace reported Q4 2025 revenue of $26.6 million, a 24% year-over-year increase from $21.5 million in Q4 2024 [4][17] - RNS System revenue was $22.4 million, reflecting a 26% year-over-year growth [4][17] - Gross margin improved to 77.4%, up from 75.4% in Q4 2024, driven by higher margin RNS revenue and manufacturing efficiencies [18] - Adjusted EBITDA was positive at $900,000, marking a $1.9 million improvement year-over-year [22] - For the full year 2025, total revenue grew 25% to $100 million, with RNS System sales also increasing by 25% [24] Business Line Data and Key Metrics Changes - The core RNS business continues to show strong growth, with a 29% increase in the second half of 2025 [5] - Service revenue from data collaborations was approximately $890,000 in Q4 2025 [17] - Revenue from DIXI Medical was about $3 million, a 4% decline compared to Q4 2024, as the commercial partnership ended [17] Market Data and Key Metrics Changes - The majority of growth is coming from Level 4 centers, indicating increased adoption and utilization of the RNS System [5] - The company is expanding access to RNS therapy through community pathways and referral networks [5] Company Strategy and Development Direction - NeuroPace is focused on deepening adoption within the adult focal epilepsy indication while preparing for future indication expansions [5][8] - The company is investing in its commercial organization, including sales representative additions and nurse navigator resources [8] - The submission of a PMA supplement to the FDA for an expanded indication in idiopathic generalized epilepsy (IGE) is a key strategic move [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a minimum of 20% growth in the core RNS business for 2026 [6] - The company reiterated its 2026 revenue guidance of $98 million to $100 million, assuming 20%-22% growth in the core RNS business [7][26] - Management highlighted the importance of ongoing investments in commercial activities and product development to drive future growth [31] Other Important Information - The company achieved its second consecutive quarter of positive adjusted EBITDA and positive cash generation in Q4 2025 [7][22] - NeuroPace is advancing its product pipeline, including AI tools designed to enhance physician workflow and patient outcomes [10][12] Q&A Session Summary Question: How quickly can the company translate from IGE approval to revenue collection? - Management indicated that extending coverage in the private payer community is essential and that preparations are already underway [38] Question: What is the impact of pricing on RNS growth in Q4? - Management noted consistent mid-single-digit pricing increases annually, with Q4 growth primarily driven by initial implants rather than pricing changes [52][54] Question: What is the current state of capacity dynamics across implanting centers? - Management stated that there is sufficient capacity in the channel for prescribers and that nurse navigators are being employed to streamline patient flow [62][64] Question: Will SeizureID be a subscription service for physicians? - SeizureID will be included with the use of the RNS System, aimed at improving efficiency for clinicians [68][70] Question: Any updates on the pediatric NEST collaboration? - Management confirmed ongoing work with NEST to utilize real-world evidence for focal pediatric patients, with no specific submission timeline yet [82]